Zobrazeno 1 - 10
of 90
pro vyhledávání: '"John M. H. de Klerk"'
Publikováno v:
The Scientific World Journal, Vol 11, Pp 391-402 (2011)
Accurate detection of bone marrow involvement in patients with lymphoma is of crucial importance because of the prognostic and therapeutic consequences. Bone marrow trephine biopsy (BMB) is currently regarded as the method of choice for the evaluatio
Externí odkaz:
https://doaj.org/article/68d8c80b9bdf49caabfbe5738a61e788
Publikováno v:
Cancers. 14(22)
Fibroblast activation protein (FAP) could be a promising target for tumor imaging and therapy, as it is expressed ingt;90% of epithelial cancers. A high level of FAP-expression might be associated with worse prognosis in several cancer types, includi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1165c02f3c1e4517a7d8e53e420250a2
https://pubmed.ncbi.nlm.nih.gov/36428657
https://pubmed.ncbi.nlm.nih.gov/36428657
Autor:
Elizabeth J, de Koster, Wyanne A, Noortman, Jacob M, Mostert, Jan, Booij, Catherine B, Brouwer, Bart, de Keizer, John M H, de Klerk, Wim J G, Oyen, Floris H P, van Velden, Lioe-Fee, de Geus-Oei, Dennis, Vriens
Publikováno v:
European journal of nuclear medicine and molecular imaging. 49(7)
To evaluate whether quantitative [Prospectively included patients with a Bethesda III or IV thyroid nodule underwent [Of 123 included patients, 84 (68%) index nodules were visually [Quantitative [This trial is registered with ClinicalTrials.gov: NCT0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::805fe458cd7f23fceea7f2cf72ae0a30
https://pubmed.ncbi.nlm.nih.gov/35138444
https://pubmed.ncbi.nlm.nih.gov/35138444
Autor:
B.H.E. Jansen, Maurits Wondergem, Reindert J.A. van Moorselaar, John M. H. de Klerk, Ronald Boellaard, Robin W. Jansen, Daniela E. Oprea-Lager, Otto S. Hoekstra, Sandra Srbljin, André N. Vis, Birgit I. Lissenberg-Witte
Publikováno v:
Jansen, B H E, Jansen, R W, Wondergem, M, Srbljin, S, de Klerk, J M H, Lissenberg-Witte, B I, Vis, A N, van Moorselaar, R J A, Boellaard, R, Hoekstra, O S & Oprea-Lager, D E 2020, ' Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for 18 F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 61, no. 2, pp. 210-216 . https://doi.org/10.2967/jnumed.118.222513
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 61(2), 210-216
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 61(2), 210-216
Biochemically recurrent prostate cancer (BCR) is the main indication to perform prostate-specific membrane antigen PET/CT. However, localizing BCR with prostate-specific membrane antigen PET/CT remains challenging in patients with low prostate-specif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136535a8b4fb7f7f90f0f65ae83d05e1
https://research.vumc.nl/en/publications/917f32da-fba5-4a5d-aa3f-948e6445b583
https://research.vumc.nl/en/publications/917f32da-fba5-4a5d-aa3f-948e6445b583
Autor:
Hugo J. A. Adams, Thomas C. Kwee, Maarten Nix, Stefan V. Dubois, John M. H. de Klerk, Ben G F Heggelman
Publikováno v:
Seminars in Nuclear Medicine. 47:322-351
Positron emission tomography with the radiotracer F-18-fluoro-2-deoxy-D-glucose (FDG) plays an important role in the evaluation of bone pathology. However, FDG is not a cancer-specific agent, and knowledge of the differential diagnosis of benign FDG-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f86e8ee6ba6acbbaaf5cc5f969416fd
https://doi.org/10.1053/j.semnuclmed.2017.02.004
https://doi.org/10.1053/j.semnuclmed.2017.02.004
Autor:
Rob ter Heine, Marco van Vulpen, Anko Kooistra, Geert W.J. Frederix, Anke M. Hövels, Haiko J. Bloemendal, Joost W Geenen, John M. H. de Klerk
Publikováno v:
Journal of Comparative Effectiveness Research, 6, 7, pp. 575-581
Journal of Comparative Effectiveness Research, 6, 575-581
Journal of Comparative Effectiveness Research, 6, 575-581
Aim: To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs). Methods: We performed a bottom-up cost of illness study in The Netherlands. Results: A total of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aea1262d7f3058587aa6790749f909e
https://hdl.handle.net/2066/182725
https://hdl.handle.net/2066/182725
Autor:
Bernard H E, Jansen, Robin W, Jansen, Maurits, Wondergem, Sandra, Srbljin, John M H, de Klerk, Birgit I, Lissenberg-Witte, André N, Vis, Reindert J A, van Moorselaar, Ronald, Boellaard, Otto S, Hoekstra, Daniela E, Oprea-Lager
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 61(2)
Biochemically recurrent prostate cancer (BCR) is the main indication to perform prostate-specific membrane antigen PET/CT. However, localizing BCR with prostate-specific membrane antigen PET/CT remains challenging in patients with low prostate-specif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3b2a6b43e51a83b9f5e16acc286c2b52
https://pubmed.ncbi.nlm.nih.gov/31481580
https://pubmed.ncbi.nlm.nih.gov/31481580
Autor:
Anko Kooistra, H. Peter Kaldeway, Peter C. de Bruin, Bart de Keizer, Richard P. Meijer, John M. H. de Klerk, Marnix G.E.H. Lam, Arthur J. A. T. Braat, Harm H.E. van Melick, Ludwike W. M. van Kalmthout, Jules Lavalaye
Publikováno v:
The Journal of urology. 203(3)
Prospective validation ofPatients with newly diagnosed prostate cancer and negative bone scan findings at greater than 10% MSKCC (Memorial Sloan Kettering Cancer Center) risk for lymph node metastasis were prospectively included in study from October
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b39970f450f02afb8d994688a61bac60
https://pubmed.ncbi.nlm.nih.gov/32282267
https://pubmed.ncbi.nlm.nih.gov/32282267
Autor:
Rob ter Heine, John M. H. de Klerk, Rogier Lange, Jocye M. Van Dodewaard-de Jong, Alfons J.M. van den Eertwegh, Haiko J. Bloemendal, Henk M.W. Verheul, Esther W. Bouman-Wammes
Publikováno v:
Clinical Genitourinary Cancer, 17, e281-e292
Bouman-Wammes, E W, de Klerk, J M H, Bloemendal, H J, Van Dodewaard-de Jong, J M, Lange, R, ter Heine, R, Verheul, H M W & Van den Eertwegh, A J M 2019, ' Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone ', Clinical Genitourinary Cancer, vol. 17, no. 2, pp. e281-e292 . https://doi.org/10.1016/j.clgc.2018.11.014
Clinical Genitourinary Cancer, 17, 2, pp. e281-e292
Bouman-Wammes, E W, de Klerk, J M H, Bloemendal, H J, Van Dodewaard-de Jong, J M, Lange, R, ter Heine, R, Verheul, H M W & Van den Eertwegh, A J M 2019, ' Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone ', Clinical Genitourinary Cancer, vol. 17, no. 2, pp. e281-e292 . https://doi.org/10.1016/j.clgc.2018.11.014
Clinical Genitourinary Cancer, 17, 2, pp. e281-e292
Item does not contain fulltext In patients with metastatic castration-resistant prostate cancer, bone is the most common site for metastases. Because of their osteoblastic character, these lesions are very suitable for treatment with bone-seeking rad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9576a2398bf7da9e4300f13aba91daa3
http://hdl.handle.net/2066/205220
http://hdl.handle.net/2066/205220
Autor:
John M. H. de Klerk, Henk M.W. Verheul, Lotty Hooft, Haiko J. Bloemendal, Alfons J.M. van den Eertwegh, Joyce M. van Dodewaard-de Jong, Daniela E. Oprea-Lager, Otto S. Hoekstra
Publikováno v:
European Urology, 70(3), 416-426. Elsevier
van Dodewaard-de Jong, J M, Oprea-Lager, D E, Hooft, L, de Klerk, J M H, Bloemendal, H J, Verheul, H M W, Hoekstra, O S & van den Eertwegh, A J M 2016, ' Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review ', European Urology, vol. 70, no. 3, pp. 416-426 . https://doi.org/10.1016/j.eururo.2015.09.005
European Urology, 70(3), 416. Elsevier
van Dodewaard-de Jong, J M, Oprea-Lager, D E, Hooft, L, de Klerk, J M H, Bloemendal, H J, Verheul, H M W, Hoekstra, O S & van den Eertwegh, A J M 2016, ' Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review ', European Urology, vol. 70, no. 3, pp. 416-426 . https://doi.org/10.1016/j.eururo.2015.09.005
European Urology, 70(3), 416. Elsevier
Context The majority of patients with castration-resistant prostate cancer develop bone metastatic disease. It is often challenging to optimally palliate malignant bone pain. In case of multifocal pain due to diffuse osteoblastic metastases, treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07ab6364c2d3931a5203f2921b485c1a
https://doi.org/10.1016/j.eururo.2015.09.005
https://doi.org/10.1016/j.eururo.2015.09.005